JAC Advance Access originally published online on July 23, 2009
Journal of Antimicrobial Chemotherapy 2009 64(4):786-793; doi:10.1093/jac/dkp262
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Original research |
Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis
1 Department of Clinical Microbiology, Kalmar County Hospital, Kalmar, Sweden 2 Department of Bacteriology, Swedish Institute of Disease Control (SMI), Stockholm, Sweden 3 Department of Clinical Microbiology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden 4 Department of Clinical Microbiology, Malmö University Hospital, Malmö, Sweden 5 Department of Clinical Microbiology, Växjö Hospital, Växjö, Sweden 6 Department of Medical Sciences, Uppsala University, Uppsala, Sweden
Received 13 March 2009; returned 12 May 2009; revised 4 June 2009; accepted 23 June 2009
* Corresponding author. Tel: +46-480-81567; Fax: +46-480-81738; E-mail: thomassc{at}ltkalmar.se
Objectives: The aim of this study was to establish wild-type MIC distributions of first-line drugs for Mycobacterium tuberculosis, as well as to explore the usefulness of such distributions when setting clinical breakpoints.
Methods: We determined the MICs of rifampicin, isoniazid and ethambutol for M. tuberculosis using a Middlebrook 7H10 dilution method for 90 consecutive clinical isolates, 8 resistant strains and 16 isolates from the WHO proficiency test panel. M. tuberculosis H37Rv was used for quality control and susceptibility results using 7H10 were compared with the results obtained with BACTEC460.
Results: The agreement with BACTEC460 was very high for isoniazid (99.1%) and rifampicin (99.1%) but lower for ethambutol (94.7%). Intra- and inter-assay variation was below one MIC dilution. The MIC distributions for isoniazid and rifampicin provided a clear separation between susceptible and resistant strains. Regarding ethambutol, the current breakpoint for 7H10 (5 mg/L) is close to the wild-type and all strains (n = 6) showing a disagreement between BACTEC460 and 7H10 were distributed very close to the breakpoint (MIC 4–8 mg/L). This problematic relation was confirmed by investigating isolates from the WHO panel with an agreement <95% (64%–88% among 26 laboratories, n = 4) for which the MICs were 4–8 mg/L.
Conclusions: Utilizing the wild-type MIC distribution was found to be as useful in M. tuberculosis as in other bacteria when setting clinical breakpoints. We suggest that the present clinical breakpoints should be re-evaluated, taking into account wild-type MIC distributions and available pharmacokinetic data.
Keywords: pharmacokinetics , rifampicin , isoniazid , ethambutol , susceptibility testing
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. Safi, R. D. Fleischmann, S. N. Peterson, M. B. Jones, B. Jarrahi, and D. Alland Allelic Exchange and Mutant Selection Demonstrate that Common Clinical embCAB Gene Mutations Only Modestly Increase Resistance to Ethambutol in Mycobacterium tuberculosis Antimicrob. Agents Chemother., January 1, 2010; 54(1): 103 - 108. [Abstract] [Full Text] [PDF]
|
|